Aspiration & Biopsy Needles Market: Competitive Analysis, Growth Strategies Based on Type, Past Data, Applications, Region and End User2022-2032

The aspiration and biopsy needles market is forecasted to be worth US$ 0.87 billion in 2021, with a CAGR of 7% forecast to hit US$ 1.83 billion by 2032.

Many growth-promoting factors are driving the aspiration and biopsy needles market, along with rising demand for minimally invasive surgeries, greater cancer awareness campaigns by global health organizations and governments, and rising cancer diagnoses.

Cancer screening, cancer management visits, and cancer biopsy procedures have all decreased significantly due to the COVID-19 pandemic. In addition, cancer screening operations were hampered due to the lockdowns, resulting in a reduction in demand for biopsy needles.

Since March 2020, COVID-19 has resulted in a substantial drop in imaging operations (for all modalities).

Download the Report Sample here: https://www.futuremarketinsights.com/reports/sample/rep-gb-14287

The aspiration and biopsy needles market players have an opportunity to expand their presence in the unexplored aspiration and biopsy needles market of emerging nations. For example, in the Middle East and Asia-Pacific, the senior population and cancer prevalence rapidly rise, yet biopsies are mostly administered using the standard surgical approach.

Emerging economies such as India, China, and South Korea provide market participants with high-growth potential. As a result, the Asia Pacific market is predicted to grow at the fastest CAGR during the forecast period.

The driving factors of the aspiration and biopsy needles market are fueling the global of this regional aspiration and biopsy needles market are increased government initiatives for cancer diagnostics and screening, increased research activities, and the high incidence of cancer in significant Asia Pacific countries such as India and China.

As a result, enterprises in the area have begun merging several imaging modalities to improve the operation and lower the cost for patients. Furthermore, as individuals in this country become more informed about efficient cancer diagnostic procedures, aspiration and biopsy needles market manufacturers have the potential to expand by focusing on developing-country clients.

“India is facing an acute shortage of oncologists, radiotherapists, and surgical oncologists. With 1.8 million cancer patients in the country, there is only one oncologist to treat every 2,000 patients.”

Radiologists and surgeons use biopsy needles to examine abnormalities at a specific site. Since these treatments include cuts and incisions for obtaining tissue samples, patients may become infected. In addition, aspiration and biopsy needles are frequently reused, which raises the risk of infection during these operations. Although the reuse of biopsy needles is discouraged by healthcare authorities and product manufacturers, the practice persists, particularly in underdeveloped nations.

Buy Report from this link: https://www.futuremarketinsights.com/checkout/14287

Odida obodo

To expand their portfolio and streamline the competition, manufacturers in the aspiration and biopsy needles market have acquired other companies in recent years.

Olympus Corporation, Boston Scientific Corporation, Medtronic plc, Stryker Corporation, Becton, Dickinson and Company, Argon Medical Devices Inc., CONMED Corporation, Merit Medical Systems Inc., Sterylab s.r.l., Cook Medical LLC, and Cardinal Health Inc. are among the significant global aspiration and biopsy needles market manufacturers.

The following are some noteworthy developments in this aspiration and biopsy needles market’s competitive landscape:

• In September of last year, Olympus Corporation of Tokyo gained FDA certification for its EZ Shot Plus 25 G needle.
• Olympus Corporation, based in Tokyo, introduced aspiration biopsy needles with Side Port – Reusable to the market in April 2016. (NA-2C-1)
• In the United States, Cook Group Incorporated released the EchoTipProCore 20 Gage Needle a few years ago. It was designed for ezigbo agịga biopsy with ultrasound guidance (FNB).
• In January 2021, Hologic, Inc. acquired SOMATEX Medical Technologies GmbH, a leader in biopsy site biomarkers, for USD 64.00 million. The acquisition funds Hologic, Inc.’s strategy to deliver a varied range of novel solutions for breast cancer treatment. Hologic, Inc. would be able to expand the breast cancer marker Pọtụfoliyo.

Etu ụzọ dị mkpa:

• Site na 2026, uwa niile aspiration and the biopsy needle are estimated to reach US$ 1.29 billion.
• Core agịga biopsy (CNB) is the most common type of biopsy, accounting for over 47% of the total aspiration and biopsy needle market na 2019.
• Hospitals accounted for 74.3% of the entire aspiration and biopsy needle market na 2019.
• North America is the world’s largest consumer area, accounting for 35.2% of worldwide aspiration and biopsy needle market sales in 2019.
• Europe is a significant consumer aspiration and biopsy needle market, accounting for 30.46% of worldwide sales.
• Vacuum-assisted biopsy, biopsy guns, and biopsy forceps and punches will all develop at far faster rates than Fine Needle Aspiration, with CAGRs of 3.97 percent, 3.70 percent, and 1.63 percent, respectively.

Download the TOC of this Report with figures: https://www.futuremarketinsights.com/reports/aspiration-and-biopsy-needles-market/table-of-content

 Banyere ngalaba nlekọta ahụike na nleba anya ahịa n'ọdịnihu

Ọdịnihu Azụmahịa Ọdịnihu na-eme ka ụlọ ọrụ, gọọmentị, ndị na-etinye ego na ndị na-ege ntị na ngalaba ahụike aka ịchọpụta ma mesie akụkụ dị mkpa ọdabara na atụmatụ ngwaahịa, nhazi nhazi, mgbanwe teknụzụ na okwu ndị ọzọ dị oke mkpa iji nweta ọganiihu na-adigide. Ụzọ pụrụ iche anyị si achịkọta ọgụgụ isi ahịa na-akwado gị n'ichepụta ụzọ ọhụrụ na-akwalite maka azụmahịa gị. Mara ihe gbasara mkpuchi ngalaba anyị ebe a

Banyere Ntụle Ahịa Ọdịnihu (FMI)
Ọdịnihu Market Insights (FMI) bụ onye na-eweta ọgụgụ isi ahịa na ọrụ ndụmọdụ, na-ejere ndị ahịa ozi n'ihe karịrị mba 150. FMI bụ isi na Dubai, ma nwee ebe nnyefe na UK, US na India. Akụkọ nyocha ahịa FMI kachasị ọhụrụ na nyocha ụlọ ọrụ na-enyere ndị azụmaahịa aka ịnyagharị ihe ịma aka ma mee mkpebi siri ike na ntụkwasị obi na idoanya n'etiti asọmpi mgbaji olu. Akụkọ nyocha ahịa anyị ahaziri ahazi yana arụkọ ọrụ na-enye nghọta nwere ike ime nke na-akwalite uto na-adigide. Otu ndị ọkachamara na-eduzi na FMI na-aga n'ihu na-agbaso usoro na mmemme na-apụta n'ọtụtụ ụlọ ọrụ iji hụ na ndị ahịa anyị kwadoro maka mkpa na-agbanwe nke ndị na-azụ ahịa ha.

Kpọtụrụ anyị:
Ọdịnihu Market Market
Nkeji Mba: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Ụlọ elu Jumeirah Lakes, Dubai,
United Arab Emirates
Maka ajụjụ ahịa: [email protected]
Maka ajụjụ mgbasa ozi: [email protected]
Weebụsaịtị: https://www.futuremarketinsights.com